Zolmigren (zolmitriptan) coated tablets 2.5 mg. №2

Description

Zolmigren (zolmitriptan) coated tablets 2.5 mg. №2

Composition

active substance: zolmitriptan;

1 tablet contains zolmitriptan in terms of 100% substance 2.5 mg;

Excipients: lactose monohydrate, microcrystalline cellulose 102, sodium starch glycolate (type A), magnesium stearate;

shell composition: Sepifilm 752 Blanc (hydroxypropylmethylcellulose, microcrystalline cellulose, polyethylene glycol (macrogol 40), titanium dioxide (E 171)), iron oxide yellow (E 172).

Dosage form

Film-coated tablets.

Main physical and chemical properties: round tablets with a biconvex surface, film-coated, pale brown-yellow color.

Pharmacotherapeutic group

Remedies used for migraines. Selective agonists of 5HT1 serotonin receptors. Zolmitriptan. ATX code N02C C03.

Pharmacological properties

Zolmigren (zolmitriptan) is a selective agonist of recombinant 5-HT1B / 1D receptors in human vascular serotonin. Has a moderate affinity for serotonin 5-HT1A receptors, has no significant affinity or pharmacological activity for 5HT2-, 5HT3-, 5HT4- serotonin receptors, a1-, a2-, b1-adrenergic receptors, H1-, H2-histamino -choline receptors, D1-, D2-dopaminergic receptors. Zolmigren (zolmitriptan) causes vasoconstriction of predominantly cranial vessels, blocking the release of neuropeptides, in particular the vasoactive intestinal peptide, which is the main effector transmitter of reflex excitation that causes vasodilatation, which is the basis of vasodilatation, which is not the basis of pathogenesis. Suspends the development of migraine attacks without direct analgesic action. Together with the relief of migraine attacks relieves nausea, vomiting (especially in left-handed attacks), photo- and phonophobia. In addition to its peripheral effects, it affects the centers of the brain stem associated with migraine, which explains the persistent re-effect in the treatment of a series of multiple migraine attacks in one patient. Highly effective in the complex treatment of migraine status (a series of several severe, successive migraine attacks lasting 2-5 days). Eliminates migraine associated with menstruation. High doses have a sedative effect and cause drowsiness.

The effect of Zolmigren (zolmitriptan) occurs in 15-20 minutes and reaches a maximum in 1 hour after ingestion. The maximum effect is observed when taking during the development of the attack.

Indication

Migraine attack relief with and without aura.

Contraindication:

• increased individual sensitivity to the components of the drug;
• uncontrolled hypertension
  coronary heart disease. Angiospastic angina (Princemetal angina);
• history of cerebrovascular disorders and transient ischemic attack (TIA);
• concomitant use of ergotamine, ergotamine derivatives, sumatriptan, naratriptan or other 5HT1B / 1D receptor agonists.

Method of application and dosage

The drug Zolmigren (zolmitriptan) is not intended for use in the prevention of migraine attacks. The effectiveness of treatment does not depend on how long after the onset of a migraine attack the drug Zolmigren® was taken, but it is recommended to use it as soon as possible after the onset of a migraine attack.

Adults should be prescribed 1 tablet (2.5 mg of zolmitriptan). If symptoms persist or recur within 24 hours, a repeated dose of 1 tablet (2.5 mg zolmitriptan) may be required. If necessary, the repeated dose can be taken no earlier than 2 hours after the first dose.

If the dose of 2.5 mg is insufficient, the single dose may be increased to 5 mg (maximum single dose). The maximum daily dose is 10 mg.

In patients responding to treatment, significant efficacy is seen within 1 hour after taking the drug.

Children

Not recommended for use in children (under 18 years).

Overdose

Symptoms. A sedative effect was observed in volunteers receiving a single 50 mg dose of zolmitriptan.

Treatment. The half-life of zolmitriptan is 2.5 to 3 hours, so the patient should be monitored after an overdose of at least 15 hours or until symptoms resolve. There is no specific antidote.

In case of severe intoxication, intensive care procedures are recommended, including airway patency, adequate oxygenation and ventilation, monitoring and maintenance of cardiovascular function.

Side effects

Side effects are usually mild, usually transient, appear within 4 hours after taking the drug, do not become more frequent after repeated use and disappear spontaneously without any additional treatment.

• from the heart: a feeling of palpitations;
• from the nervous system: sensitivity, dizziness, headache, hyperesthesia, paresthesia, drowsiness, fever;
• from the gastrointestinal tract: abdominal pain, nausea, vomiting, dry mouth, dysphagia;
• from the musculoskeletal system and connective tissue: muscle weakness, muscle pain;
• general disorders and administration site conditions: asthenia, heaviness, tightness, pain or pressure in the throat, neck, chest and extremities.